Status and phase
Conditions
Treatments
About
Full description
Safety
Efficacy (Immunogenicity)
-GMT(Geometric Mean Titer) and GMR(Geometric Mean Ratio(fold change))measured by the glycoprotein enzyme-linked immunosorbent assay (gpELISA) at before and 42 days after the IP administration
Exploratory assessment
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
230 participants in 3 patient groups
Loading...
Central trial contact
Hye Won Shin
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal